On Friday 9 June, the European Commission approved the proposed acquisition of Actelion Pharmaceuticals by Johnson & Johnson, subject to conditions ensuring that the transaction has no negative effects on the clinical development of their innovative insomnia drugs.
Actelion Pharmaceuticals and Johnson & Johnson are both active in the development and sales of innovative pharmaceutical products. The Commission’s examination of the planned transaction, which was notified on 12 April of this...